AbbVie Net Income 2010-2022 | ABBV

AbbVie annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • AbbVie net income for the quarter ending March 31, 2022 was $4.490B, a 26.37% increase year-over-year.
  • AbbVie net income for the twelve months ending March 31, 2022 was $12.479B, a 141.89% increase year-over-year.
  • AbbVie annual net income for 2021 was $11.542B, a 150.04% increase from 2020.
  • AbbVie annual net income for 2020 was $4.616B, a 41.44% decline from 2019.
  • AbbVie annual net income for 2019 was $7.882B, a 38.6% increase from 2018.
AbbVie Annual Net Income
(Millions of US $)
2021 $11,542
2020 $4,616
2019 $7,882
2018 $5,687
2017 $5,309
2016 $5,953
2015 $5,144
2014 $1,774
2013 $4,128
2012 $5,275
2011 $3,433
2010 $4,178
2009 $4,637
AbbVie Quarterly Net Income
(Millions of US $)
2022-03-31 $4,490
2021-12-31 $4,044
2021-09-30 $3,179
2021-06-30 $766
2021-03-31 $3,553
2020-12-31 $36
2020-09-30 $2,308
2020-06-30 $-738
2020-03-31 $3,010
2019-12-31 $2,801
2019-09-30 $1,884
2019-06-30 $741
2019-03-31 $2,456
2018-12-31 $-1,826
2018-09-30 $2,747
2018-06-30 $1,983
2018-03-31 $2,783
2017-12-31 $52
2017-09-30 $1,631
2017-06-30 $1,915
2017-03-31 $1,711
2016-12-31 $1,391
2016-09-30 $1,598
2016-06-30 $1,610
2016-03-31 $1,354
2015-12-31 $1,517
2015-09-30 $1,239
2015-06-30 $1,366
2015-03-31 $1,022
2014-12-31 $-810
2014-09-30 $506
2014-06-30 $1,098
2014-03-31 $980
2013-12-31 $1,128
2013-09-30 $964
2013-06-30 $1,068
2013-03-31 $968
2012-12-31 $1,540
2012-09-30 $1,585
2012-06-30 $1,267
2012-03-31 $883
2011-12-31 $1,157
2011-09-30 $13
2011-06-30 $1,540
2011-03-31 $723
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $266.851B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.705B 17.91
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07